ArticleTurkish journal of surgery2026
Potential use of bioresorbable poly-D-L-lactic acid (PDLLA) plates in rhinoseptoplasty.
Article in Turkish journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Bioresorbable poly-D-L-lactic acid (PDLLA) plates are increasingly used in rhinoseptoplasty due to their biocompatibility, adequate initial mechanical strength, and complete resorption over time. These properties may offer advantages over permanent implants, particularly in complex cases involving post-traumatic nasal deformity. To evaluate the clinical efficacy and safety of PDLLA plates in achieving functional and aesthetic outcomes in primary and reconstructive rhinoseptoplasty. Material and Methods: A retrospective cohort study was conducted on 37 consecutive patients [23 men, 14 women; median age 37 years, interquartile range (IQR) 30-44] who underwent rhinoseptoplasty between January 2022 and December 2024. The minimum follow-up was 3 months. Primary endpoints included septal stability, complication profile (e.g., infection, extrusion, resorption issues), and patient-reported outcomes. Subjective nasal appearance and symptom burden were assessed using the validated Standardized Cosmesis and Health Nasal Outcomes Survey (SCHNOS). In select cases requiring revision, histopathological evaluation of implantation sites was performed at 12 and 24 months. Results: He use of pure PDLLA plates provided reliable septal stabilization and facilitated precise dorsal alignment, eliminating the need for autologous graft harvesting in 83.8% of cases. No plate-related infections, extrusions, or delayed resorption events were observed. Patient-reported symptom burden, as measured by the SCHNOS score, improved markedly from a median of 21 (IQR: 15-26) preoperatively to 1 (IQR: 0-1) postoperatively. Histology confirmed complete material resorption by 24 months, with mature collagenous remodeling and an absence of chronic inflammatory infiltrate. Conclusion: In carefully selected patients, PDLLA plates appear to be a biocompatible and technically feasible adjunct in rhinoseptoplasty, facilitating septal reconstruction, eliminating donor-site morbidity, and yielding improvements in both patient-reported nasal function and aesthetic outcomes. These preliminary findings support further investigation in larger, controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.